PMID- 23098573
OWN - NLM
STAT- MEDLINE
DCOM- 20130718
LR  - 20200502
IS  - 1938-0666 (Electronic)
IS  - 1526-8209 (Linking)
VI  - 13
IP  - 1
DP  - 2013 Feb
TI  - Managing ixabepilone adverse events with dose reduction.
PG  - 1-6
LID - S1526-8209(12)00182-6 [pii]
LID - 10.1016/j.clbc.2012.09.003 [doi]
AB  - Ixabepilone is a synthetic analogue of epothilone B approved for the treatment of 
      patients with metastatic or locally advanced breast cancer in combination with 
      capecitabine for cancer resistant to an anthracycline and a taxane, and as 
      monotherapy for cancer resistant or refractory to anthracyclines, taxanes, and 
      capecitabine. The principal dose-limiting adverse events (AEs) of ixabepilone's 
      standard dose (40 mg/m(2) administered by 3-hour infusion once every 3 weeks) are 
      peripheral neuropathy, neutropenia, and fatigue. An effective strategy to manage 
      ixabepilone-related AEs is dose reduction by 20% (from 40 to 32 to 25 mg/m(2)); 
      this does not appear to affect treatment efficacy and enables continuation of 
      treatment after recovery (grade 1 or resolved). When appropriate, treatment can 
      be restarted with a 20% dose reduction (to 32 mg/m(2)). For heavily pretreated 
      patients, especially those with a low performance status, 32 mg/m(2) is an 
      appropriate initial dose; the dose of capecitabine should also be lowered by 20%. 
      Weekly ixabepilone (15-20 mg/m(2) on days 1, 8, and 15 every 28 days) may have an 
      improved tolerability profile, but prospective studies with a large number of 
      patients are required to determine whether it has therapeutic benefit comparable 
      with the current approved regimen. More information is required on dosage and 
      scheduling of ixabepilone in combination with other agents, including novel 
      targeted therapies.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Valero, Vicente
AU  - Valero V
AD  - Department of Breast Medical Oncology, Division of Cancer Medicine, the Morgan 
      Welch Inflammatory Breast Cancer Research Program and Clinic, The University of 
      Texas MD Anderson Cancer Center, Houston, TX, USA. vvalero@mdanderson.org
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20121024
PL  - United States
TA  - Clin Breast Cancer
JT  - Clinical breast cancer
JID - 100898731
RN  - 0 (Epothilones)
RN  - K27005NP0A (ixabepilone)
SB  - IM
MH  - Breast Neoplasms/*drug therapy
MH  - Disease Management
MH  - Dose-Response Relationship, Drug
MH  - Epothilones/*administration & dosage
MH  - Female
MH  - Humans
EDAT- 2012/10/27 06:00
MHDA- 2013/07/19 06:00
CRDT- 2012/10/27 06:00
PHST- 2012/05/24 00:00 [received]
PHST- 2012/08/31 00:00 [revised]
PHST- 2012/09/13 00:00 [accepted]
PHST- 2012/10/27 06:00 [entrez]
PHST- 2012/10/27 06:00 [pubmed]
PHST- 2013/07/19 06:00 [medline]
AID - S1526-8209(12)00182-6 [pii]
AID - 10.1016/j.clbc.2012.09.003 [doi]
PST - ppublish
SO  - Clin Breast Cancer. 2013 Feb;13(1):1-6. doi: 10.1016/j.clbc.2012.09.003. Epub 
      2012 Oct 24.